首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran.
【24h】

A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran.

机译:米那普仑缓解成人注意力不足/多动障碍的情况。

获取原文
获取原文并翻译 | 示例
           

摘要

Concerning medical treatments for adult attention-deficit/hyperactivity disorder (AD/HD), case reports have gradually been accumulating on the efficacy of psychostimulants such as methylphenidate and amphetamine and selective noradrenaline reuptake inhibitors such as atomoxetine. However, patients intolerant to psychostimulants currently have a very limited range of treatments available to them. Here, we report a case of an adult AD/HD patient whose inattention and hyperactivity were remarkably alleviated by milnacipran, a serotonin noradrenaline reuptake inhibitor. Milnacipran has fewer side effects than comparable drugs, and we believe it could be developed into a good curative treatment for AD/HD in the future.
机译:关于成人注意力缺乏/多动障碍(AD / HD)的药物治疗,关于精神兴奋药(如哌醋甲酯和苯丙胺)和选择性去甲肾上腺素再摄取抑制剂(如阿莫西汀)的疗效的病例报告已逐渐积累。但是,目前对精神兴奋药不耐受的患者所能接受的治疗范围非常有限。在这里,我们报告了一个成人AD / HD患者的病例,该患者的注意力不集中和活动过度被5-羟色胺去甲肾上腺素再摄取抑制剂米那普仑显着缓解。米那普仑的副作用比同类药物少,我们相信将来它可以发展成为AD / HD的良好治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号